Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies During Tyrosine Kinase Inhibitor Treatment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We aimed to investigate the feasibility of four criteria on oligometastasis (OM) concerning clear survival benefits of local therapy (LT) during tyrosine kinase inhibitor (TKI) treatment in non–small cell lung cancer (NSCLC). Materials and Methods This single-center, retrospective study included patients with advanced NSCLC who received LT because of OM during TKI treatment at Asan Medical Center from January 2011 to December 2020. At the application of LT OM was classified according to four criteria: TNM, European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC-LCG), National Comprehensive Network (NCCN), and ORGAN. We compared survival outcomes between patients with and without OM. Results The median overall survival of the 117 patients included in the analysis was 70.8 months (95% confidence interval [CI], 56.6 to 85.1). The patients with OM meeting all four criteria (hazard ratio [HR] with 95% CI of TNM criteria 0.24 with 0.10-0.57; p=0.001, EORTC-LCG criteria 0.34 with 0.17-0.67; p=0.002, NCCN criteria 0.41 with 0.20-0.86; p=0.018 and ORGAN criteria 0.33 with 0.18-0.60; p < 0.001) had significantly longer survival compared with patients who did not after adjusting for confounding factors. Furthermore, increasing the number of extra-thoracic metastatic organs to two or more were independent predictive factors for worse survival outcomes (2 organs: HR, 3.51; 95% CI, 1.01 to 12.14; p=0.048; 3 organs: HR, 4.31; 95% CI, 0.94 to 19.73; p=0.060; 4 organs: HR, 24.47; 95% CI, 5.08 to 117.80; p < 0.001). Conclusion Patients with OM defined by all four criteria showed prognostic benefits from LT during TKI therapy.
Abstract
Purpose We aimed to investigate the feasibility of four criteria on oligometastasis (OM) concerning clear survival benefits of local therapy (LT) during tyrosine kinase inhibitor (TKI) treatment in non–small cell lung cancer (NSCLC). Materials and Methods This single-center, retrospective study included patients with advanced NSCLC who received LT because of OM during TKI treatment at Asan Medical Center from January 2011 to December 2020. At the application of LT OM was classified according to four criteria: TNM, European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC-LCG), National Comprehensive Network (NCCN), and ORGAN. We compared survival outcomes between patients with and without OM. Results The median overall survival of the 117 patients included in the analysis was 70.8 months (95% confidence interval [CI], 56.6 to 85.1). The patients with OM meeting all four criteria (hazard ratio [HR] with 95% CI of TNM criteria 0.24 with 0.10-0.57; p=0.001, EORTC-LCG criteria 0.34 with 0.17-0.67; p=0.002, NCCN criteria 0.41 with 0.20-0.86; p=0.018 and ORGAN criteria 0.33 with 0.18-0.60; p < 0.001) had significantly longer survival compared with patients who did not after adjusting for confounding factors. Furthermore, increasing the number of extra-thoracic metastatic organs to two or more were independent predictive factors for worse survival outcomes (2 organs: HR, 3.51; 95% CI, 1.01 to 12.14; p=0.048; 3 organs: HR, 4.31; 95% CI, 0.94 to 19.73; p=0.060; 4 organs: HR, 24.47; 95% CI, 5.08 to 117.80; p < 0.001). Conclusion Patients with OM defined by all four criteria showed prognostic benefits from LT during TKI therapy.
참고문헌 (29)
- Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
- Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
- Camidge DR, "Acquired resistance to TKIs in solid tumours : learning from lung cancer", Nat Rev Clin Oncol, 11, pp.473~481 (2014)
- Li XY, "Analysis of progression patterns and failure sites of patients with metastatic lung adenocarcinoma with EGFR mutations receiving first-line treatment of tyrosine kinase inhibitors", Clin Lung Cancer, 21, pp.534~544 (2020)
- Xu Q, "Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs", J Thorac Oncol, 13, pp.1383~1392 (2018)
- Ashworth AB, "An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer", Clin Lung Cancer, 15, pp.346~355 (2014)
- Weichselbaum RR, "Oligometastases revisited", Nat Rev Clin Oncol, 8, pp.378~382 (2011)
- Palma DA, "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers(SABR-COMET) : a randomised, phase 2, open-label trial", Lancet, 393, pp.2051~2058 (2019)
- Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 2. 2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
- Guckenberger M, "Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation", Lancet Oncol, 21, pp.e18~28 (2020)
- Blumenthaler AN, "Classifying oigometastatic non-small cell lung cancer", Cancers(Basel), 13, pp.4822~ (2021)
- Detterbeck FC, "The eighth edition lung cancer stage classification", Chest, 151, pp.193~203 (2017)
- Dingemans AC, "Definition of synchronous oligometastatic non-small cell lung cancer : a consensus report", J Thorac Oncol, 14, pp.2109~2119 (2019)
- Correa RJ, "Stereotactic body radiotherapy for oligometastasis : opportunities for biology to guide clinical management", Cancer J, 22, pp.247~256 (2016)
- Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Paz-Ares L, "Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer : overall survival data from the phase IIb LUX-Lung 7 trial", Ann Oncol, 28, pp.270~277 (2017)
- Gerlinger M, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N Engl J Med, 366, pp.883~892 (2012)
- Naxerova K, "Using tumour phylogenetics to identify the roots of metastasis in humans", Nat Rev Clin Oncol, 12, pp.258~272 (2015)
- Valastyan S, "Tumor metastasis : molecular insights and evolving paradigms", Cell, 147, pp.275~292 (2011)
- Fidler IJ, "The pathogenesis of cancer metastasis : the ‘seed and soil’ hypothesis revisited", Nat Rev Cancer, 3, pp.453~458 (2003)
- Yu HA, "Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors", J Thorac Oncol, 8, pp.346~351 (2013)
- Wu YL, "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, open-label, phase 3 trial", Lancet Oncol, 18, pp.1454~1466 (2017)
- Gan GN, "Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib", Int J Radiat Oncol Biol Phys, 88, pp.892~898 (2014)
- Weickhardt AJ, "Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer", J Thorac Oncol, 7, pp.1807~1814 (2012)
- Shaw AT, "First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer", N Engl J Med, 383, pp.2018~2029 (2020)
- Lussier YA, "Oligo-and polymetastatic progression in lung metastasis(es)patients is associated with specific microRNAs", PLoS One, 7, pp.e50141~ (2012)
- Uppal A, "14q32-encoded microRNAs mediate an oligometastatic phenotype", Oncotarget, 6, pp.3540~3552 (2015)
- Marusyk A, "Tumor heterogeneity : causes and consequences", Biochim Biophys Acta, 1805, pp.105~117 (2010)
- Warton K, "Methylated circulating tumor DNA in blood : power in cancer prognosis and response", Endocr Relat Cancer, 23, pp.R157~71 (2016)